The abovementioned studies demonstrate that various blood-based biomarkers, including microRNAs, metabolites, and proteins biomarkers, have the potential to serve as early diagnostic tools for feline mammary cancer that is essential for the development of new diagnostic and therapeutic strategies, which might help improve the prognosis and survival rate of affected cats. Further research is necessary to validate these biomarkers and develop practical clinical applications. Early detection and treatment of feline mammary cancer remain critical to the successful management of this disease.